We can’t show the full text here under this license.
Abstract
A 76-year-old woman developed acute hepatitis after 8 weeks of tirzepatide use, coinciding with a sixteen-pound weight loss.
- Tirzepatide is an injectable medication for type 2 diabetes and obesity.
- There are few reported cases of (DILI) associated with tirzepatide.
- The patient exhibited elevated liver enzymes, indicating liver dysfunction.
- Liver biopsy confirmed the diagnosis of DILI.
- The mechanism behind this liver injury is currently unknown.
- Awareness of this rare side effect is important for healthcare providers.
Simplified